Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, experimentation, industrialisation/scaling, adoption, and monetisation.
The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast.
The ways in which HCPs prefer to engage with pharma has been changing for quite some time, and the digital transformation brought by COVID has dramatically accelerated that.
Life sciences software company Axtria has received a $150 million investment from Bain Capital Tech Opportunities to expand its suite of AI-platforms for omnichannel commercial operations.<
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year